Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells

Autophagy

Volumn 9, Issue 10, 2013, Pages 1509-1526

  Chiao, Ming Tsang ^a   Cheng, Wen Yu ^b   Yang, Yi Chin ^b   Shen, Chiung Chyi ^b,c,d,e   Ko, Jiunn Liang ^a,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e HUNGKUANG UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AKT MTOR signaling; Autophagy; Chloroquine; Glioblastoma stem cells; SAHA

Indexed keywords

3 METHYLADENINE; ACETYLCYSTEINE; BAFILOMYCIN A1; BECLIN 1; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; VORINOSTAT; WORTMANNIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL AGING; CELL DEATH; CELL DIFFERENTIATION; CELL LEVEL; CELL ORGANELLE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CYTOLOGY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHAGOSOME; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NEOPLASTIC STEM CELLS; PHAGOSOMES; SIGNAL TRANSDUCTION;

EID: 84885639981     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.25664     Document Type: Article

References (63)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21:2683-710; PMID:17974913; http://dx.doi.org/10.1101/gad.1596707
2. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468:824-8; PMID:21102434; http://dx.doi.org/10.1038/nature09557
3. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468:829-33; PMID:21102433; http://dx.doi.org/10.1038/nature09624
4. Chiao MT, Yang YC, Cheng WY, Shen CC, Ko JL. CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo. Curr Neurovasc Res 2011; 8:210-9; PMID:21675958; http://dx.doi.org/10.2174/156720211796558023
5. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60; PMID:17051156; http://dx.doi.org/10.1038/nature05236
6. Johannessen TC, Bjerkvig R, Tysnes BB. DNA repair and cancer stem-like cells-potential partners in glioma drug resistance? Cancer Treat Rev 2008; 34:558-67; PMID:18501520; http://dx.doi.org/10.1016/j.ctrv.2008.03.125
7. Coates JM, Galante JM, Bold RJ. Cancer therapy beyond apoptosis: autophagy and anoikis as mechanisms of cell death. J Surg Res 2010; 164:301-8; PMID:20031162; http://dx.doi.org/10.1016/j.jss.2009.07.011
8. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005; 23:2411-22; PMID:15800333; http://dx.doi.org/10.1200/JCO.2005.03.089
9. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, Thompson CB. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005; 120:237-48; PMID:15680329; http://dx.doi.org/10.1016/j. cell.2004.11.046
10. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009; 43:67-93; PMID:19653858; http://dx.doi.org/10. 1146/annurev-genet-102808-114910
11. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R, Kroemer G. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 2009; 16:87-93; PMID:18806760; http://dx.doi.org/10.1038/cdd.2008. 131
12. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006; 10:51-64; PMID:16843265; http://dx.doi.org/10.1016/j.ccr.2006.06.001
13. Gozuacik D, Kimchi A. Autophagy and cell death. Curr Top Dev Biol 2007; 78:217-45; PMID:17338918; http://dx.doi.org/10.1016/S0070-2153(06)78006-1
14. Hashimoto D, Ohmuraya M, Hirota M, Yamamoto A, Suyama K, Ida S, Okumura Y, Takahashi E, Kido H, Araki K, et al. Involvement of autophagy in trypsinogen activation within the pancreatic acinar cells. J Cell Biol 2008; 181:1065-72; PMID:18591426; http://dx.doi.org/10.1083/jcb.200712156
15. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009; 1:62-71; PMID:19966939
16. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109:31-9; PMID:16960145; http://dx.doi.org/10.1182/blood- 2006-06-025999
17. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr., Pal A, Bornmann WG, Chiao PJ, Huang P, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66:3773-81; PMID:16585204; http://dx.doi.org/10.1158/0008-5472. CAN-05-2961
18. Sangeetha SR, Singh N, Vender JR, Dhandapani KM. Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. Endocrine 2009; 35:389-96; PMID:19291426; http://dx.doi.org/10.1007/ s12020-009-9159-1
19. Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACimediated apoptosis in leukemic cells. Leukemia 2008; 22:819-25; PMID:18239621; http://dx.doi.org/10.1038/leu.2008.1
20. Brahmachari S, Fung YK, Pahan K. Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 2006; 26:4930-9; PMID:16672668; http://dx.doi.org/10.1523/JNEUROSCI.5480-05.2006
21. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6:1057-65; PMID:20962572; http://dx.doi.org/10.4161/ auto.6.8.13365
22. Li J, Liu R, Lei Y, Wang K, Lau QC, Xie N, Zhou S, Nie C, Chen L, Wei Y, et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy 2010; 6:711-24; PMID:20543569; http://dx.doi.org/10.4161/auto.6.6. 12397
23. Bjørkøy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtininduced cell death. J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.org/10.1083/jcb. 200507002
24. Gammoh N, Marks PA, Jiang X. Curbing autophagy and histone deacetylases to kill cancer cells. Autophagy 2012; 8:1521-2; PMID:22894919; http://dx.doi.org/10.4161/auto.21151
25. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A 2012; 109:6561-5; PMID:22493260; http://dx.doi.org/10. 1073/pnas.1204429109
26. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306:990-5; PMID:15528435; http://dx.doi.org/10.1126/ science.1099993
27. Cao Q, Yu C, Xue R, Hsueh W, Pan P, Chen Z, Wang S, McNutt M, Gu J. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int J Biochem Cell Biol 2008; 40:272-83; PMID:17881280; http://dx.doi.org/10.1016/j.biocel.2007. 07.020
28. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000; 275:992-8; PMID:10625637; http://dx.doi.org/10.1074/jbc.275.2.992
29. Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 2010; 285:10850-61; PMID:20123989; http://dx.doi.org/10.1074/jbc.M109. 080796
30. Giansanti V, Torriglia A, Scovassi AI. Conversation between apoptosis and autophagy: Is it your turn or mine?. Apoptosis 2011; 16:321-33; PMID:21404107; http://dx.doi.org/10.1007/s10495-011-0589-x
31. Basu S, Ganguly A, Chakraborty P, Sen R, Banerjee K, Chatterjee M, Efferth T, Choudhuri SK. Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff 's base to overcome MDR in cancer. Biochimie 2012; 94:166-83; PMID:22037022; http://dx.doi.org/10. 1016/j.biochi.2011.10.004
32. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007; 110:313-22; PMID:17363733; http://dx.doi.org/10. 1182/blood-2006-10-050260
33. Fariss MW, Chan CB, Patel M, Van Houten B, Orrenius S. Role of mitochondria in toxic oxidative stress. Mol Interv 2005; 5:94-111; PMID:15821158; http://dx.doi.org/10.1124/mi.5.2.7
34. Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 2009; 11:777-90; PMID:18828708; http://dx.doi.org/10.1089/ars.2008.2270
35. Dictus C, Tronnier V, Unterberg A, Herold-Mende C. Comparative analysis of in vitro conditions for rat adult neural progenitor cells. J Neurosci Methods 2007; 161:250-8; PMID:17207861; http://dx.doi.org/10.1016/j.jneumeth.2006.11. 012
36. Ziegler DS, Kung AL, Kieran MW. Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 2008; 26:493-500; PMID:18202424; http://dx.doi.org/10. 1200/JCO.2007.13.9717
37. Bertrand J, Begaud-Grimaud G, Bessette B, Verdier M, Battu S, Jauberteau MO. Cancer stem cells from human glioma cell line are resistant to Fasinduced apoptosis. Int J Oncol 2009; 34:717-27; PMID:19212677
38. Zhuang W, Li B, Long L, Chen L, Huang Q, Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011; 129:2720-31; PMID:21384342; http://dx.doi.org/10.1002/ijc. 25975
39. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151-75; PMID:18188003
40. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, Moroni F, Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol 2006; 70:1876-84; PMID:16946032; http://dx.doi.org/10.1124/mol.106.027912
41. Di Bernardo G, Squillaro T, Dell'Aversana C, Miceli M, Cipollaro M, Cascino A, Altucci L, Galderisi U. Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem Cells Dev 2009; 18:573-81; PMID:18694296; http://dx.doi.org/10.1089/scd.2008.0172
42. Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007; 6:2967-75; PMID:18025281; http://dx.doi.org/10.1158/1535-7163.MCT-04-0344
43. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6:e27746; PMID:22140466; http://dx.doi.org/10.1371/journal.pone.0027746
44. Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 2009; 4:e5747; PMID:19484127; http://dx.doi.org/10.1371/journal. pone.0005747
45. Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Cañon E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megias D, Mulero F, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 2009; 16:103-14; PMID:19647221; http://dx.doi.org/10.1016/j.ccr.2009.07.004
46. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004; 101:18030-5; PMID:15596714; http://dx.doi.org/10.1073/pnas.0408345102
47. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25:1025-40; PMID:15657430; http://dx.doi.org/10.1128/MCB.25.3.1025-1040.2005
48. Ciechomska IA, Goemans GC, Skepper JN, Tolkovsky AM. Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function. Oncogene 2009; 28:2128-41; PMID:19347031; http://dx.doi.org/10.1038/onc.2009.60
49. Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquineinduced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12:473-81; PMID:20406898
50. Kim EL, Wüstenberg R, Rübsam A, Schmitz-Salue C, Warnecke G, Bücker EM, Pettkus N, Speidel D, Rohde V, Schulz-Schaeffer W, et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol 2010; 12:389-400; PMID:20308316; http://dx.doi.org/10.1093/ neuonc/nop046
51. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137:1062-75; PMID:19524509; http://dx.doi.org/10. 1016/j.cell.2009.03.048
52. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7:961-7; PMID:17972889; http://dx.doi.org/10.1038/nrc2254
53. O'Donovan TR, O'Sullivan GC, McKenna SL. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011; 7:509-24; PMID:21325880; http://dx.doi.org/10.4161/auto.7.5.15066
54. Guo XL, Li D, Hu F, Song JR, Zhang SS, Deng WJ, Sun K, Zhao QD, Xie XQ, Song YJ, et al. Targeting autophagy potentiates chemotherapyinduced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett 2012; 320:171-9; PMID:22406827; http://dx.doi.org/10.1016/j.canlet.2012.03.002
55. Chen N, Debnath J. Autophagy and tumorigenesis. FEBS Lett 2010; 584:1427-35; PMID:20035753; http://dx.doi.org/10.1016/j.febslet.2009.12.034
56. Goss P, Allan AL, Rodenhiser DI, Foster PJ, Chambers AF. New clinical and experimental approaches for studying tumor dormancy: does tumor dormancy offer a therapeutic target? APMIS 2008; 116:552-68; PMID:18834402
57. Fan QW, Weiss WA. Autophagy and Akt promote survival in glioma. Autophagy 2011; 7:536-8; PMID:21266843; http://dx.doi.org/10.4161/auto.7.5.14779
58. Sundberg AL, Steffen AC. Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases. Int J Radiat Oncol Biol Phys 2007; 67:279-87; PMID:17189076; http://dx.doi.org/10.1016/j.ijrobp.2006.07.1369
59. Young AR, Narita M, Ferreira M, Kirschner K, Sadaie M, Darot JF, Tavare S, Arakawa S, Shimizu S, Watt FM, et al. Autophagy mediates the mitotic senescence transition. Genes Dev 2009; 23:798-803; PMID:19279323; http://dx.doi.org/10.1101/gad.519709
60. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280:125-33; PMID:19359091; http://dx.doi.org/10.1016/j.canlet.2009.02.042
61. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16:1246-52; PMID:17548692; http://dx.doi.org/10.1158/1055-9965.EPI-07-0022
62. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7:455-65; PMID:20531380; http://dx.doi.org/10.1038/nrclinonc.2010.82
63. Hsin IL, Sheu GT, Chen HH, Chiu LY, Wang HD, Chan HW, Hsu CP, Ko JL. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells. Mutat Res 2010; 688:72-7; PMID:20363232; http://dx.doi.org/10.1016/j.mrfmmm.2010.03.011